what is mitral regurgitation (mr)?...for more information visit about 1 in 10 people age and older...

1
WHAT IS MITRAL REGURGITATION (MR)? The mitral valve has two leaflets that open and close to ensure blood flows in only one direction within the heart. Sometimes the valve doesn't seal completely and blood leaks backwards inside the heart – a condition called mitral regurgitation. TREATMENT OPTIONS MR is a progressive disease that can severely impact quality of life, resulting in an inability to perform simple day-to-day tasks. SEVERE MR CAN CAUSE SHORTNESS OF BREATH FATIGUE AND EXHAUSTION COUGHING SENSATIONS OF RAPID, FLUTTERING HEARTBEAT Doctors can often make the initial diagnosis of MR using a stethoscope to listen for the sound of a murmur in your heart. Additional tests to confirm a diagnosis include an echocardiogram (ultrasound of the heart) or an exercise stress test. THE GOAL OF TREATMENT IS TO REDUCE MR AND IMPROVE QUALITY OF LIFE. Physicians may prescribe medicines to reduce symptoms caused by MR. However, the medicines do not address the underlying mechanical problem that causes MR. MITRAL VALVE SURGERY IS AN EFFECTIVE TREATMENT FOR MR, BUT SOME PATIENTS CANNOT HAVE SURGERY DUE TO THEIR RISK OF DEATH AND COMPLICATIONS. TREATMENT WITH THE MITRACLIP DEVICE MAY BE AN OPTION FOR PATIENTS WHO HAVE SIGNIFICANT SYMPTOMATIC DEGENERATIVE MR AND ARE AT PROHIBITIVE RISK FOR SURGERY. The mitral valve is vital to the operation of your heart and your body. 2 1 HEART FAILURE COSTS THE UNITED STATES $34.4 BILLION EACH YEAR. 1 1 Heidenriech PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44. MR CAN LEAD TO HEART FAILURE, A POTENTIALLY DEADLY CONDITION THAT OCCURS WHEN THE HEART IS UNABLE TO DISTRIBUTE BLOOD SUFFICIENTLY TO MEET THE NEEDS OF THE BODY. ESTIMATES INDICATE THAT 8 MILLION PEOPLE IN THE U.S. AND EUROPE ALONE HAVE MR. 2 IN SOME CASES, DOCTORS MAY RECOMMEND SURGICAL TREATMENT. There are two types of surgery to reduce MR: Performed when repair is not suitable; replaces the damaged valve. The preferred surgical approach in most cases; preserves the mitral valve. MITRAL VALVE REPLACEMENT MITRAL VALVE REPAIR THE CATHETER-BASED MITRACLIP REDUCES SIGNIFICANT MR BY CLIPPING TOGETHER THE LEAFLETS OF THE MITRAL VALVE. The heart beats normally during the procedure, and therefore a heart-lung bypass machine is not necessary. The MitraClip device provides a new option for patients with significant symptomatic degenerative MR who have no other effective treatment options. The clip is delivered to the heart through a small incision in the femoral vein, a blood vessel in the leg. FEMORAL VEIN Clinical data from patients treated with the MitraClip device consistently demonstrate safety, reduction of mitral regurgitation, rapid recovery, improvement in symptoms, and reduction in hospitalizations for heart failure. 2 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11. http://www.ncbi.nlm.nih.gov/pubmed/16980116. For more information visit www.abbott.com ABOUT 1 IN 10 PEOPLE AGE AND OLDER HAVE MR. 2 75 MITRAL VALVE Indication: The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation. Additional information about MitraClip, including important safety information, is available online at http://www.abbottvascular.com/static/cms_workspace/pdf/ifu/structural_heart/eIFU_MitraClip.pdf © 2013 Abbott. All rights reserved. For media use only. All drawings are artist’s representations only and should not be considered as an engineering drawing or photograph. MitraClip is a trademark of the Abbott Group of Companies. PML04150 Rev. A

Upload: others

Post on 28-Feb-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: WHAT IS MITRAL REGURGITATION (MR)?...For more information visit ABOUT 1 IN 10 PEOPLE AGE AND OLDER HAVE MR. 75 2 MITRAL VALVE Indication: The MitraClip Clip Delivery System is indicated

WHAT IS MITRAL REGURGITATION (MR)?

The mitral valve has two leaflets that open and close to ensure blood flows in only one direction within the heart.

Sometimes the valve doesn't seal completely and blood leaks backwards inside the heart – a condition called mitral regurgitation.

TREATMENT OPTIONS

MR is a progressive disease that can severely impact quality of life, resulting in an inability to perform simple day-to-day tasks.

SEVERE MR CAN CAUSE

SHORTNESS OF BREATH

FATIGUE AND EXHAUSTION

COUGHING

SENSATIONS OF RAPID, FLUTTERING HEARTBEAT

Doctors can often make the initial diagnosis of MR using a stethoscope to listen for the sound of a murmur in your heart.

Additional tests to confirm a diagnosis include an echocardiogram (ultrasound of the heart)or an exercise stress test.

THE GOAL OF TREATMENT IS TO REDUCE MR AND IMPROVE QUALITY OF LIFE.

Physicians may prescribe medicines to reduce symptoms caused by MR. However, the medicines do not address the underlying mechanical problem that causes MR.

MITRAL VALVE SURGERY IS AN EFFECTIVE TREATMENT FOR MR, BUT SOME PATIENTS CANNOT HAVE SURGERY DUE TO THEIR RISK OF DEATH AND COMPLICATIONS.

TREATMENT WITH THE MITRACLIP DEVICE MAY BE AN OPTION FOR PATIENTS WHO HAVE SIGNIFICANT SYMPTOMATIC DEGENERATIVE MR AND ARE AT PROHIBITIVE RISK FOR SURGERY.

The mitral valve is vital to the operation of your heart and your body.

21

HEART FAILURE COSTS THE

UNITED STATES $34.4 BILLION

EACH YEAR.1

1 Heidenriech PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.

MR CAN LEAD TO HEART FAILURE,

A POTENTIALLY DEADLY

CONDITION THAT OCCURS WHEN

THE HEART IS UNABLE TO

DISTRIBUTE BLOOD SUFFICIENTLY

TO MEET THE NEEDS OF THE BODY.

ESTIMATES INDICATE THAT 8 MILLION PEOPLE IN THE U.S. AND EUROPE ALONE HAVE MR.2

IN SOME CASES, DOCTORS MAY RECOMMEND SURGICAL TREATMENT.

There are two types of surgery to reduce MR:

Performed when repair is not suitable; replaces the damaged valve.

The preferred surgical approach in most cases; preserves the mitral valve.

MITRAL VALVE REPLACEMENTMITRAL VALVE REPAIR

THE CATHETER-BASED MITRACLIP REDUCES SIGNIFICANT MR BY CLIPPING TOGETHER THE LEAFLETS OF THE MITRAL VALVE.

The heart beats normally during the procedure, and therefore a heart-lung bypass machine is not necessary.

The MitraClip device provides a new option for patients with significant symptomatic degenerative MR who have no other effective treatment options. The clip is delivered to the heart through

a small incision in the femoral vein, a blood vessel in the leg.

FEMORAL VEIN

Clinical data from patients treated with the MitraClip device consistently demonstrate safety, reduction of mitral regurgitation, rapid recovery, improvement in symptoms, and reduction in hospitalizations for heart failure.

2 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11. http://www.ncbi.nlm.nih.gov/pubmed/16980116.

For more information visit www.abbott.com

ABOUT 1 IN 10 PEOPLE AGE AND OLDER HAVE MR.2 75

MITRAL VALVE

Indication: The MitraClip Clip Delivery System is indicated for the percutaneous reduction of signi�cant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected bene�t from reduction of the mitral regurgitation.

Additional information about MitraClip, including important safety information, is available online at http://www.abbottvascular.com/static/cms_workspace/pdf/ifu/structural_heart/eIFU_MitraClip.pdf

© 2013 Abbott. All rights reserved. For media use only. All drawings are artist’s representations only and should not be considered as an engineering drawing or photograph. MitraClip is a trademark of the Abbott Group of Companies. PML04150 Rev. A